Deutsche Bank AG boosted its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 66.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,551,865 shares of the company's stock after purchasing an additional 1,017,500 shares during the period. Deutsche Bank AG owned about 4.19% of Pliant Therapeutics worth $33,608,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PLRX. China Universal Asset Management Co. Ltd. grew its position in shares of Pliant Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,903 shares of the company's stock worth $170,000 after buying an additional 1,209 shares in the last quarter. Swiss National Bank lifted its stake in Pliant Therapeutics by 1.6% in the fourth quarter. Swiss National Bank now owns 95,700 shares of the company's stock valued at $1,260,000 after acquiring an additional 1,500 shares during the last quarter. Atria Investments Inc boosted its holdings in Pliant Therapeutics by 18.1% during the fourth quarter. Atria Investments Inc now owns 11,821 shares of the company's stock valued at $156,000 after acquiring an additional 1,812 shares during the period. R Squared Ltd acquired a new stake in Pliant Therapeutics in the 4th quarter worth $33,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Pliant Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 459,384 shares of the company's stock worth $6,050,000 after purchasing an additional 2,721 shares during the period. Hedge funds and other institutional investors own 97.30% of the company's stock.
Pliant Therapeutics Trading Down 3.6%
PLRX traded down $0.05 during midday trading on Monday, hitting $1.33. 129,726 shares of the company were exchanged, compared to its average volume of 1,077,170. The firm has a market capitalization of $81.64 million, a P/E ratio of -0.40 and a beta of 1.43. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. Pliant Therapeutics, Inc. has a 1-year low of $1.10 and a 1-year high of $16.10. The firm's 50 day moving average price is $1.46 and its 200-day moving average price is $7.35.
Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.17. As a group, equities analysts forecast that Pliant Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on PLRX. Leerink Partnrs lowered Pliant Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 3rd. Needham & Company LLC reaffirmed a "hold" rating and set a $10.00 price target on shares of Pliant Therapeutics in a research note on Tuesday, March 4th. JPMorgan Chase & Co. downgraded shares of Pliant Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, February 10th. Stifel Nicolaus downgraded shares of Pliant Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, Oppenheimer restated a "market perform" rating on shares of Pliant Therapeutics in a research note on Monday, February 10th. Twelve research analysts have rated the stock with a hold rating, According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $13.31.
Get Our Latest Research Report on Pliant Therapeutics
Pliant Therapeutics Company Profile
(
Free Report)
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
See Also
Before you consider Pliant Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.
While Pliant Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
